Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jun;10(2):199-213.
doi: 10.1007/s11523-014-0333-x. Epub 2014 Sep 12.

Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: an overview for pharmacists

Jean-Baptiste Rey  1 , Vincent Launay-Vacher, Christophe Tournigand
Affiliations
Review

Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: an overview for pharmacists

Jean-Baptiste Rey et al. Target Oncol. 2015 Jun.

Abstract

Regorafenib (BAY 73-4506, Stivarga® Bayer HealthCare Pharmaceutical Inc) is an oral multikinase inhibitor with a distinct and wide-ranging profile of tyrosine kinase inhibition, resulting in antiangiogenic and antiproliferative properties in tumors. Single-agent regorafenib administered as a 160-mg daily dose for the first 21 days of a 28-day cycle is approved for use in patients with pretreated metastatic colorectal cancer (mCRC) and gastrointestinal stromal tumor (GIST) progressing on imatinib and sunitinib, following publication of data from the phase III CORRECT and GRID studies respectively. Regorafenib is currently under phase III investigation in patients with hepatocellular carcinoma and is in several phase II studies in patients with gastrointestinal (GI) tumors. This review describes the clinical development of regorafenib in patients with GI cancers, and highlights the key issues important for the modern day clinical pharmacist who forms part of the multidisciplinary team ensuring safe and effective delivery of the drug to the patient. This information is considered of particular importance to the clinical pharmacist for the future development of regorafenib in this treatment setting.

PubMed Disclaimer

References

    1. Hu QD, Zhang Q, Chen W, Bai XL, Liang TB. Human development index is associated with mortality-to-incidence ratios of gastrointestinal cancers. World J Gastroenterol. 2013;19:5261–5270. doi: 10.3748/wjg.v19.i32.5261. - DOI - PMC - PubMed
    1. Prenen H, Vecchione L, Van Cutsem E. Role of targeted agents in metastatic colorectal cancer. Target Oncol. 2013;8:83–96. doi: 10.1007/s11523-013-0281-x. - DOI - PubMed
    1. Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde CJ, Balmana J, Regula J, Nagtegaal ID, Beets-Tan RG, Arnold D, Ciardiello F, Hoff P, Kerr D, Kohne CH, Labianca R, Price T, Scheithauer W, Sobrero A, Tabernero J, Aderka D, Barroso S, Bodoky G, Douillard JY, El Ghazaly H, Gallardo J, Garin A, Glynne-Jones R, Jordan K, Meshcheryakov A, Papamichail D, Pfeiffer P, Souglakos I, Turhal S, Cervantes A. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol. 2012;23:2479–2516. doi: 10.1093/annonc/mds236. - DOI - PubMed
    1. National Comprehensive Cancer Network Guidelines Colon Cancer Version 3.2013 http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
    1. Glivec® summary of product characteristics http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Info...

Publication types

MeSH terms

LinkOut - more resources